The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 12, 2021

Filed:

Sep. 01, 2015
Applicant:

Bellicum Pharmaceuticals, Inc., Houston, TX (US);

Inventors:

David Spencer, Houston, TX (US);

Aaron Edward Foster, Houston, TX (US);

Kevin Slawin, Houston, TX (US);

Assignee:

Bellicum Pharmaceuticals, Inc., Houston, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/09 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); C12N 9/64 (2006.01); C12N 9/90 (2006.01); C07K 14/47 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 39/00117 (2018.08); A61K 39/001104 (2018.08); A61K 39/001106 (2018.08); A61K 39/001112 (2018.08); A61K 39/001124 (2018.08); A61K 39/001168 (2018.08); A61K 39/001171 (2018.08); A61K 39/001188 (2018.08); A61K 39/001189 (2018.08); A61K 39/001193 (2018.08); A61K 39/001195 (2018.08); C07K 14/4702 (2013.01); C07K 14/70578 (2013.01); C12N 9/6472 (2013.01); C12N 9/90 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2319/03 (2013.01); C07K 2319/70 (2013.01); C12Y 304/22062 (2013.01); C12Y 502/01008 (2013.01);
Abstract

The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen. The technology also relates to costimulation of therapeutic cells that express chimeric antigen receptors that recognize target antigens using chimeric MyD88- and CD40-derived polypeptides. The technology further relates in part to therapeutic cells that express chimeric antigen receptors, wherein the chimeric antigen receptors have an endodomain that includes MyD88- and CD40-derived polypeptides, and methods for treating patients using the modified therapeutic cells.


Find Patent Forward Citations

Loading…